NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
NASDAQ · ESTA · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Establishment Labs Holdings Inc.’s quoted price sits in the lower half of its reported 52-week range, 29.9% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Establishment Labs Holdings Inc.’s next earnings report is currently expected on Feb 23, 2027, with estimated earnings per share of -$0.07. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Establishment Labs Holdings Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Establishment Labs Holdings Inc. operates as a medical technology enterprise specializing in the creation and commercialization of devices for aesthetic and reconstructive plastic surgery. The company is primarily recognized for its silicone gel-filled breast implants, sold under the Motiva Implants brand. Among these are the Motiva Ergonomix and Motiva Ergonomix2, which are distinctive, gravity-sensitive, round, soft silicone-gel-filled implants. Furthermore, Establishment Labs provides the Motiva Flora Tissue Expander for breast tissue and distributes the Puregraft range of products, utilized for the harvesting and redistribution of autologous adipose tissue. The firm markets its offerings across Europe, Latin America, the Asia-Pacific region, and other global markets, leveraging both a direct sales force and exclusive distributors. Founded in 2004, Establishment Labs has its main office situated in Alajuela, Costa Rica.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:56 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2025 | Aug 7, 2025 | -$0.57-5.56% vs estimate | $51.30M-2.25% vs estimate |
|---|
| Q1 2025 | May 7, 2025 | -$0.70+15.66% vs estimate | $41.38M+0.64% vs estimate |
|---|
| Q4 2024 | Feb 26, 2025 | -$0.98-53.12% vs estimate | $44.51M+0.15% vs estimate |
|---|
THE ANALYST VIEW
14 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 5 contributors · Median target $95.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
$275.20+$4.16 (+1.53%)
Johnson & Johnson’s quoted price sits in the upper half of its reported 52-week range, 2.09% below the high.
$290.97+$4.98 (+1.74%)
AbbVie Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.55% below the high.
$410.91+$3.81 (+0.94%)
UnitedHealth Group Incorporated’s quoted price sits in the upper half of its reported 52-week range, 10.99% below the high.
$146.33+$5.40 (+3.83%)
Merck & Co., Inc.’s quoted price sits in the upper half of its reported 52-week range, 6.75% below the high.
$12.83+$0.59 (+4.82%)
Integra LifeSciences Holdings Corporation’s quoted price sits in the lower half of its reported 52-week range, 37.38% below the high.
$13.51+$0.14 (+1.05%)
InMode Ltd.’s quoted price sits in the lower half of its reported 52-week range, 18.96% below the high.
$0.92-$0.06 (-5.74%)
TELA Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 38.67% below the high.
